- Home
- SBSI vs GHRS Comparison
SBSI vs GHRS Comparison
Compare SBSI & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SBSI | GHRS |
|---|---|---|
| Founded | 1960 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 974.1M | 947.2M |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SBSI | GHRS |
|---|---|---|
| Price | $32.96 | $23.18 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $35.33 | ★ $41.38 |
| AVG Volume (30 Days) | 64.3K | ★ 190.3K |
| Earning Date | 04-30-2026 | 05-01-2026 |
| Dividend Yield | ★ 4.42% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $28.87 | N/A |
| Revenue Next Year | $5.82 | N/A |
| P/E Ratio | $42.19 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.32 | $10.96 |
| 52 Week High | $34.53 | $24.66 |
Technical Indicators
Market Signals| Indicator | SBSI | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 53.56 | 63.43 |
| Support Level | $31.73 | $12.65 |
| Resistance Level | $34.06 | $24.66 |
| Average True Range (ATR) | 0.69 | 1.48 |
| MACD | 0.02 | -0.09 |
| Stochastic Oscillator | 82.03 | 81.11 |
Price Performance
Historical ComparisonAbout SBSI Southside Bancshares Inc.
Southside Bancshares Inc is a bank holding company. Through its subsidiary, it operates as a financial institution offering various financial services to individuals, businesses, municipal entities, and nonprofit organizations. These services include consumer and commercial loans, deposit accounts, wealth management and trust services, brokerage services, and safe deposit services. The company's primary market areas are East Texas, Southeast Texas, and the greater Dallas-Fort Worth, Austin, and Houston, Texas.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.